JP2016520053A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520053A5 JP2016520053A5 JP2016512207A JP2016512207A JP2016520053A5 JP 2016520053 A5 JP2016520053 A5 JP 2016520053A5 JP 2016512207 A JP2016512207 A JP 2016512207A JP 2016512207 A JP2016512207 A JP 2016512207A JP 2016520053 A5 JP2016520053 A5 JP 2016520053A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tumstatin
- amino acid
- cd137l
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310162738.3 | 2013-05-06 | ||
| CN201310162738.3A CN103214584B (zh) | 2013-05-06 | 2013-05-06 | 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用 |
| CN201310163407.1A CN103232543B (zh) | 2013-05-06 | 2013-05-06 | 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用 |
| CN201310163407.1 | 2013-05-06 | ||
| PCT/CN2014/076768 WO2014180288A1 (zh) | 2013-05-06 | 2014-05-05 | 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520053A JP2016520053A (ja) | 2016-07-11 |
| JP2016520053A5 true JP2016520053A5 (enExample) | 2018-05-31 |
Family
ID=51866722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512207A Pending JP2016520053A (ja) | 2013-05-06 | 2014-05-05 | 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10875903B2 (enExample) |
| EP (1) | EP2995626B1 (enExample) |
| JP (1) | JP2016520053A (enExample) |
| DK (1) | DK2995626T3 (enExample) |
| ES (1) | ES2686968T3 (enExample) |
| WO (1) | WO2014180288A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| BR112019007267A2 (pt) * | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| LT3565579T (lt) | 2017-01-05 | 2023-09-11 | Kahr Medical Ltd. | Pd1-41bbl sulietas baltymas ir jo panaudojimo būdai |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| KR20210044221A (ko) | 2018-07-11 | 2021-04-22 | 카 메디컬 리미티드 | Pd1-4-1bbl 변이체 융합 단백질 및 이의 사용 방법 |
| US12134638B2 (en) | 2018-07-11 | 2024-11-05 | Kahr Medical Ltd. | SIRPalpha-4-1BBL variant fusion protein and methods of use thereof |
| CN116640226B (zh) * | 2022-04-02 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种抑制宿主抗外源免疫细胞hvg反应的嵌合受体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1705248A1 (en) * | 1997-10-01 | 2006-09-27 | G.D. Searle LLC. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment |
| EP1086129A1 (en) * | 1998-06-17 | 2001-03-28 | Beth Israel Deaconess Medical Center | Anti-angiogenic proteins and methods of use thereof |
| EP1501861A4 (en) * | 2002-05-06 | 2007-06-20 | Univ Texas | TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS |
| CA2575441A1 (en) * | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
| WO2009086132A2 (en) * | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| CN101265482A (zh) * | 2008-04-25 | 2008-09-17 | 罗以勤 | 重组肿瘤抑素-肿瘤坏死因子分泌型真核表达载体及其制备方法和用途 |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| EP3670536A3 (en) | 2011-04-01 | 2020-10-07 | Universität Stuttgart | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof |
| AU2012296588B2 (en) * | 2011-08-17 | 2017-07-27 | The Regents Of The University Of Colorado, A Body Corporate | Transferrin-tumstatin fusion protein and methods for producing and using the same |
| CN103232543B (zh) * | 2013-05-06 | 2014-12-03 | 中国药科大学 | 具有Tumstatin活性的重组蛋白Tumstatin-CD137L4及其制备和应用 |
| CN103214584B (zh) * | 2013-05-06 | 2014-07-09 | 中国药科大学 | 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用 |
-
2014
- 2014-05-05 JP JP2016512207A patent/JP2016520053A/ja active Pending
- 2014-05-05 DK DK14795356.6T patent/DK2995626T3/en active
- 2014-05-05 WO PCT/CN2014/076768 patent/WO2014180288A1/zh not_active Ceased
- 2014-05-05 US US14/895,959 patent/US10875903B2/en not_active Expired - Fee Related
- 2014-05-05 ES ES14795356.6T patent/ES2686968T3/es active Active
- 2014-05-05 EP EP14795356.6A patent/EP2995626B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520053A5 (enExample) | ||
| WO2018050039A1 (zh) | 新的抗pd-1纳米抗体及其应用 | |
| WO2016188449A1 (zh) | 一种针对cd47的单域抗体 | |
| CN114380906B (zh) | 一种抗il-17a的单域抗体及其用途 | |
| WO2017070943A1 (zh) | 双特异性抗体、其制备方法和用途 | |
| CN105837688A (zh) | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 | |
| JP2016520053A (ja) | 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用 | |
| US20190099461A1 (en) | Rna viruses for immunovirotherapy | |
| CN103319595B (zh) | 抗人afp单链抗体以及融合抗原肽的制备方法和应用 | |
| CN106928363B (zh) | 一种FAP纳米抗体Nb12 | |
| CN103570831A (zh) | 牛源性抗金黄色葡萄球菌单链抗体及其制备方法和应用 | |
| CN101451145A (zh) | 基于t细胞表位的结核基因疫苗及其制备方法和应用 | |
| WO2019109954A1 (zh) | PD-1-Fc融合蛋白及其制备方法和用途 | |
| CN103333248A (zh) | 一种cd25纳米抗体、其编码序列及应用 | |
| CN106928358B (zh) | 一种CD105纳米抗体Nb168 | |
| CN104672333A (zh) | 一种人源ctla4融合蛋白及其制备方法和应用 | |
| CN104031134B (zh) | 一种基因治疗用载体蛋白及其制备方法和用途 | |
| Qin et al. | Screening and anti‐glioma activity of Chiloscyllium plagiosum anti‐human IL‐13Rα2 single‐domain antibody | |
| CN108300725B (zh) | 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用 | |
| CN105399832A (zh) | 一种无标签单链型人源双特异性抗体及其用途 | |
| CN110903402A (zh) | 一种双特异性融合蛋白及其构建方法与应用 | |
| CN103789340A (zh) | 一种高效制备重组人mica蛋白的方法 | |
| CN106928368B (zh) | 一种FAP纳米抗体Nb57 | |
| CN106928355B (zh) | 一种CD105纳米抗体Nb184 | |
| CN106928360B (zh) | 一种CD105纳米抗体Nb68 |